Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 6/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL7251980 | 0.91 | CPB2 (0.39) | TACR1SIGMAR1ALDH1A1 | |
| SCHEMBL7246639 | 0.80 | FPR2 (0.43) | TACR1SIGMAR1 | |
| SCHEMBL7543008 | 0.75 | SIGMAR1 (0.45) | TACR1SIGMAR1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL13875780 | 0.72 | SIGMAR1 (0.50) | TACR1SIGMAR1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL3614775 | 0.72 | SIGMAR1 (0.50) | TACR1SIGMAR1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL3604123 | 0.70 | SIGMAR1 (0.65) | TACR1SIGMAR1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL5791105 | 0.69 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL4843507 | 0.69 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL4839870 | 0.69 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL27793229 | 0.68 | TACR1 (0.62) | TACR1SIGMAR1ALDH1A1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6525044-B2 | Treatment of neurological disorders related to beta -amyloid production such as Alzheimer's disease and Down's Syndrome. | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-25 | — | — | US | disclosed |
| EP-1261610-A2 | SUCCINOYLAMINO CARBOCYCLES AND HETEROCYCLES AS INHIBITORS OF A-BETA PROTEIN PRODUCTION | Bristol-Myers Squibb Pharma Company (US) | 2002-12-04 | — | — | EP | disclosed |
| US-20020055501-A1 | Succinoylamino carbocycles and heterocycles as inhibitors of a-beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-05-09 | — | — | US | disclosed |
| WO-2001060826-A2 | SUCCINOYLAMINO CARBOCYCLES AND HETEROCYCLES AS INHIBITORS OF Aβ PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055501-A1 | Succinoylamino carbocycles and heterocycles as inhibitors of a-beta protein production | APP, APH1A, APH1B | TACR1 2007/4885SIGMAR1 4527/4885ALDH1A1 3189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.